Technology area: Biotechnology & Pharmaceuticals
26 pending office actions • 13 art units • 22 examiners • 0 of 26 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Glaxosmithkline Biologicals S.A. has 26 pending office actions in Biotechnology & Pharmaceuticals. The matters span 22 distinct examiners and 13 distinct art units, showing a broad and distributed examination profile with repeated art-unit settings. Effective management will require a common portfolio framework for technical positions, disclosure support, and issue tracking, combined with application-specific response planning.
DUFFY, PATRICIA ANN is the busiest examiner, with 4 pending matters. That examiner handles a meaningful part of the docket, but the remaining matters are distributed across other assignments. Counsel should monitor recurring biotechnology and pharmaceutical issues, use consistent terminology where appropriate, and preserve distinctions that arise from different examiners, art units, or claim records.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (15%) |
| §103 only | 3 (12%) |
| §102 only | 1 (4%) |
| §112 only | 3 (12%) |
| Double-patenting only | 1 (4%) |
| Double-patenting + other | 4 (15%) |
| Multi-statute (no §101) | 10 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, PATRICIA ANN | 4 | 52.9% | +33.9% |
| LI, BAO Q | 2 | 75.5% | +26.7% |
| CHHAY, BONIRATH | 1 | 62.5% | +0.0% |
| GRASER, JENNIFER E | 1 | 76.8% | +23.2% |
| BOESEN, AGNIESZKA | 1 | 68.6% | +21.8% |
| CHATTERJEE, JAYANTA | 1 | 44.0% | +70.1% |
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
| ZEMAN, ROBERT A | 1 | 54.2% | +27.9% |
| LEONARD, ARTHUR S | 1 | 50.5% | +50.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262073 | Therapeutic Viral Vaccine | CORNELIUS, CLAIRE ADRIENNE | 49d overdue |
| 18008771 | DOCK TAG SYSTEM | COFFA, SERGIO | 28d |
| 18795336 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | LI, BAO Q | — |
| 18721985 | Method for Preparing Outer Membrane Vesicles | GRASER, JENNIFER E | — |
| 18718636 | VACCINE | DUFFY, PATRICIA ANN | — |
| 18667046 | RSV IMMUNIZATION REGIMEN | BOESEN, AGNIESZKA | — |
| 18702436 | Saponin Production | CHATTERJEE, JAYANTA | — |
| 18620109 | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | KIM, YUNSOO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17628667 | QUANTIFICATION OF BIOCONJUGATE GLYCOSYLATION | DUFFY, PATRICIA ANN | 30d overdue |
| 17618283 | MUCOSAL VACCINE FORMULATIONS | LI, BAO Q | 16d overdue |
| 18795336 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | LI, BAO Q | — |
| 18721985 | Method for Preparing Outer Membrane Vesicles | GRASER, JENNIFER E | — |
| 18718636 | VACCINE | DUFFY, PATRICIA ANN | — |
| 18667046 | RSV IMMUNIZATION REGIMEN | BOESEN, AGNIESZKA | — |
| 18702436 | Saponin Production | CHATTERJEE, JAYANTA | — |
| 18620109 | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1645 | 9 |
| 1671 | 4 |
| 1672 | 2 |
| 1641 | 2 |
| 1662 | 1 |
| 1635 | 1 |
| 1631 | 1 |
| 1685 | 1 |
| 1699 | 1 |
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18844433 | IMMUNOGENIC COMPOSITIONS | CHHAY, BONIRATH | 1645 | §103§112DP | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18795336 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | LI, BAO Q | 1671 | §102§103Other | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18721985 | Method for Preparing Outer Membrane Vesicles | GRASER, JENNIFER E | 1645 | §103§112 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18718636 | VACCINE | DUFFY, PATRICIA ANN | 1645 | §102§112 | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18667046 | RSV IMMUNIZATION REGIMEN | BOESEN, AGNIESZKA | 1672 | §101DP | Non-Final OA | — | Pending | May 17, 2024 |
| 18702436 | Saponin Production | CHATTERJEE, JAYANTA | 1662 | §103§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18620109 | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | KIM, YUNSOO | 1641 | §102§103§112Other | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18687892 | IVT RNA MANUFACTURING PROCESS | BRETZ, COREY LANE | 1635 | §102§103§112 | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18686089 | Shigella Vaccine | DUFFY, PATRICIA ANN | 1645 | §103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18438870 | MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES | ZEMAN, ROBERT A | 1645 | §103 | Non-Final OA | — | Pending | Feb 12, 2024 |
| 18508435 | LIPID FORMULATIONS WITH RNA ENCODING IMMUNOGENS | LEONARD, ARTHUR S | 1631 | §103DP | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18463099 | IMMUNOGENIC COMBINATION COMPOSITIONS AND USES THEREOF | BLUMEL, BENJAMIN P | 1671 | DP | Final Rejection | — | Pending | Sep 07, 2023 |
| 18279526 | NATURAL LANGUAGE PROCESSING TO PREDICT PROPERTIES OF PROTEINS | FONSECA LOPEZ, FRANCINI ALVARENGA | 1685 | §102§103§112DP | Non-Final OA | — | Pending | Aug 30, 2023 |
| 18262073 | Therapeutic Viral Vaccine | CORNELIUS, CLAIRE ADRIENNE | 1672 | §101§103§112Other | Final Rejection | 49d overdue | Pending | Jul 19, 2023 |
| 18262033 | Therapeutic Viral Vaccine | LY, KRISTINA ELISABETH | 1671 | §102§103§112DP | Non-Final OA | — | Pending | Jul 19, 2023 |
| 18256749 | Hyper-Blebbing Bacteria | DUFFY, PATRICIA ANN | 1645 | §101§102§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18039514 | MODIFICATION OF SAPONINS | KANE, TREVOR LOGAN | 1699 | §112 | Non-Final OA | — | Pending | May 31, 2023 |
| 18321044 | NATURAL LANGUAGE PROCESSING TO PREDICT PROPERTIES OF PROTEINS | ANDERSON-FEARS, KEENAN NEIL | 1687 | §101§102§103§112 | Non-Final OA | — | Pending | May 22, 2023 |
| 18011643 | ADJUVANTS | GOTFREDSON, GAREN | 1619 | §103 | Final Rejection | — | Pending | Dec 20, 2022 |
| 18008771 | DOCK TAG SYSTEM | COFFA, SERGIO | 1658 | §103§112 | Non-Final OA | 28d | Pending | Dec 07, 2022 |
| 17923252 | MICROFLUIDIC MIXING DEVICE AND METHODS OF USE | NGUYEN, HENRY H | 1758 | §103§112 | Non-Final OA | — | Pending | Nov 04, 2022 |
| 17918676 | SARS COV-2 SPIKE PROTEIN CONSTRUCT | DIBRINO, MARIANNE | 1641 | §103§112 | Non-Final OA | — | Pending | Oct 13, 2022 |
| 17763354 | IMMUNOGENIC COMPOSITIONS | MORGAN, BAILEY MICHELLE | 1645 | §103 | Non-Final OA | — | Pending | Mar 24, 2022 |
| 17628667 | QUANTIFICATION OF BIOCONJUGATE GLYCOSYLATION | DUFFY, PATRICIA ANN | 1645 | §112 | Final Rejection | 30d overdue | Pending | Jan 20, 2022 |
| 17618283 | MUCOSAL VACCINE FORMULATIONS | LI, BAO Q | 1671 | §102 | Final Rejection | 16d overdue | Pending | Dec 10, 2021 |
| 18425500 | BIOCONJUGATES OF E. COLI O-ANTIGEN POLYSACCHARIDES, METHODS OF PRODUCTION THEREOF, AND METHODS OF USE THEREOF | GANGLE, BRIAN J | 1645 | §112 | Non-Final OA | — | Pending | Jan 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGlaxosmithkline Biologicals S.A. has 26 pending office actions as of October 2026, spread across 13 art units and 22 examiners.
Patricia Ann Duffy has the most, with 4 of Glaxosmithkline Biologicals S.A.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
